A comparison study of CT and PET/CT for prognostic value of early response evaluation following nivolumab therapy
Latest Information Update: 10 Aug 2020
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 10 Aug 2020 New trial record